患有呼吸道过敏的成年人的过敏免疫疗法不良事件-ADER:EAACI工作组报告的数据:EAACI工作组报告
Julijana Asllani1,2, Dimitrios Mitsias3, George Konstantinou4
1Faculty of Medicine, University of Medicine, Tirana, Albania.
Allergy
|August 23, 2024
概括
过敏原免疫疗法 (AIT) 的不良反应 (AE) 在现实实践中并不常见,严重反应很少见. 喘和皮下AIT增加AE风险,而修改过敏原减少它.
科学领域:
- 过敏和免疫学 过敏和免疫学
- 临床实践研究 临床实践研究
- 药物监督 药物监督 药物监督
背景情况:
- 关于过敏原免疫疗法 (AIT) 结果的真实数据是有价值的.
- 在临床实践中缺乏对AIT不良事件 (AE) 的系统记录.
研究的目的:
- 用一个潜在的注册表来调查现实世界AIT的安全性.
- 确定与AIT相关的不良事件的频率,特征和风险因素.
主要方法:
- 使用过敏原免疫疗法不良事件登记 (ADER),这是一个前性的多中心研究.
- 分析了成年人呼吸道过敏患者的数据,他们接受了针对虫,花粉,表皮和/或菌的AIT治疗.
- 采用MedDRA术语来记录AE和调查风险因素.
主要成果:
- 1545名患者接受了1815个AIT课程;7.4%的患者经历了AE.
- 副作用在增加剂量期间比维持剂量更频繁 (59%).
- 严重反应很少发生 (0.2%),主要是皮下AIT (SCIT). 喘,SCIT和特定的过敏原 (草,猫,树) 增加了AE风险;过敏症降低了风险.
结论:
- 与AIT相关的AE在现实环境中影响少数患者,严重事件很少发生.
- 喘和SCIT已被确定为AE的危险因素.
- 修改过敏原 (过敏剂) 的使用与AE的风险较低有关.
相关概念视频
Allergic Reactions
27.3K
Overview
27.3K
Allergic Drug Reactions
824
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
824
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
254
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
254
Drugs Used in Lower Respiratory Disorders: Overview
367
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
367
Hypersensitivities
562
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
562
Antiasthma Drugs: Leukotriene Modifiers
259
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
259


